No Data
Tempus AI Publishes XF+ Assay Study Results in Journal of Molecular Diagnostics
Tempus AI Announces Publication Of Its Study 'Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy' In The Journal of Molecular Diagnostics
BTIG Maintains Tempus AI(TEM.US) With Buy Rating, Maintains Target Price $60
Tempus AI Inc Class A Call Volume Above Normal and Directionally Bullish
Analysts Split on High-Stakes 'Call Option' for Tempus AI Stock (TEM)
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}